Many topical GHK-Cu products have been studied in controlled clinical trials for skin applications, and the evidence in this domain is more developed than for systemic applications
This pathologically cardiac hypertrophy is an independent predictor of adverse cardiovascular outcomes, such as cardiovascular death, heart failure, myocardial infarction, arrhythmia, and stroke 4,5,6
There is not a single published randomized controlled trial of subcutaneous GHK-Cu in humans for any aesthetic, hair, or longevity endpoint
This dual action, reducing the cytokine signal while rebuilding the physical barrier, is what distinguishes it from single-mechanism anti-inflammatory agents
Diabetes Obes Metab, 2025
Some work mainly with diabetes patients , while others focus on weight loss only